Abstract
Treatment of malignant gliomas remains a challenge irrespective of the recent improvements. Chemotherapeutic agents for malignant gliomas have been particularly inefficient for the existence of blood-tumor barrier (BTB), which hampers the accumulation and uptake in tumor. Moreover, even though blood-brain barrier (BBB) is compromised to some extent under the situation of malignant gliomas, it remains to be the obstacle influencing the therapeutic efficacies via systemic administration. Fortunately, there are many receptors over-expressed on the BTB (glioma cells and/or tumor microvessels) that can mediate ligand modified drug delivery systems targeting to gliomas and enhance tumor uptake. On the other hand, numerous routes have also been explored to circumvent the BBB. In this manuscript, we elucidate the BBB/BTB status under the situation of malignant gliomas and review the receptors over-expressed on BTB and the malignant gliomas targeted drug delivery strategies. We also discuss the perspective of malignant gliomas targeted drug delivery systems with new concepts.
Keywords: Gliomas, blood-brain barrier, blood-tumor barrier, targeted drug delivery system, therapy, Treatment of malignant gliomas, Chemotherapeutic agents for malignant, tumor, tumor microvessels, glioma cells, glioblastoma multiforme, median survival, glioma, chemotherapeutic efficacies
Current Pharmaceutical Biotechnology
Title:The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Volume: 13 Issue: 12
Author(s): Changyou Zhan and Weiyue Lu
Affiliation:
Keywords: Gliomas, blood-brain barrier, blood-tumor barrier, targeted drug delivery system, therapy, Treatment of malignant gliomas, Chemotherapeutic agents for malignant, tumor, tumor microvessels, glioma cells, glioblastoma multiforme, median survival, glioma, chemotherapeutic efficacies
Abstract: Treatment of malignant gliomas remains a challenge irrespective of the recent improvements. Chemotherapeutic agents for malignant gliomas have been particularly inefficient for the existence of blood-tumor barrier (BTB), which hampers the accumulation and uptake in tumor. Moreover, even though blood-brain barrier (BBB) is compromised to some extent under the situation of malignant gliomas, it remains to be the obstacle influencing the therapeutic efficacies via systemic administration. Fortunately, there are many receptors over-expressed on the BTB (glioma cells and/or tumor microvessels) that can mediate ligand modified drug delivery systems targeting to gliomas and enhance tumor uptake. On the other hand, numerous routes have also been explored to circumvent the BBB. In this manuscript, we elucidate the BBB/BTB status under the situation of malignant gliomas and review the receptors over-expressed on BTB and the malignant gliomas targeted drug delivery strategies. We also discuss the perspective of malignant gliomas targeted drug delivery systems with new concepts.
Export Options
About this article
Cite this article as:
Zhan Changyou and Lu Weiyue, The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341798
DOI https://dx.doi.org/10.2174/138920112803341798 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types
Current Cancer Drug Targets Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Longitudinal Melatonin Production in Female Laboratory Rats During 1997-2006: Possible Modulatory Effects of Changing Solar Activity
Current Aging Science Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery Comparing the Interaction of Cyclophosphamide Monohydrate to Human Serum Albumin as Opposed to Holo-Transferrin by Spectroscopic and Molecular Modeling Methods: Evidence for Allocating the Binding Site
Protein & Peptide Letters Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment
Current Pharmaceutical Design Biohybrid Membrane Systems for Testing Molecules and Stem Cell Therapy in Neuronal Tissue Engineering
Current Pharmaceutical Design The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas
Current Molecular Medicine Adenovirus As An Integrating Vector
Current Gene Therapy